WILSON JAMES N sold $832K of CORT (indirect holdings)

WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $83.20 ($82.69–$83.57, $0.83M total) across 2 trades on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILSON JAMES N
Published Jun 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The newest concrete fact is the disclosed sale size ($832,048.95) and execution details (10,000 shares across two trades at ~$82.69–$83.57) filed on 2026-06-18.

02

Market read

Primarily a sentiment/positioning datapoint; unlikely to change fundamentals given the 10b5-1 pre-arrangement.

03

What to watch

10b5-1 plans are often routine and can be driven by pre-set liquidity needs or diversification rather than company outlook.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-18 (covers sale dated 2026-06-16).

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics (CORT) by director Wilson James N, indicating an open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics director Wilson James N sold $832,048.95 of CORT via an open-market sale under a pre-arranged 10b5-1 plan on 2026-06-16.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around the filing.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which reduces interpretability as new negative information.

Market effects

No sector read-through; this is a single-company insider sale disclosure.

None.

None.

Counterpoint

Because the sale is director-level and sizable, some traders may still interpret it as a mild risk signal despite the 10b5-1 framing.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction; director Wilson James N sold shares under a 10b5-1 plan.

  • Wilson James N

    Director who executed an open-market sale of 10,000 CORT shares on 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.